Oligonucleotide & ASO CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Oligonucleotide / ASO manufacturers on CDMO Signal: 36 listed, 20 with a Signal Score. Together they have 36 FDA inspections on file (including 10 NAI, 26 VAI and 0 OAI) and 82 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure solid-phase synthesis scale, backbone chemistry, or conjugation. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-31. Methodology.

Oligo/ASO CDMOs with the most regulatory evidence on file

EUROAPI
France
4 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2024-03-08 · NAI
See the evidence →
Corden Pharma
83.1
Plankstadt, DE · Caponago, IT · Boulder, CO
5 FDA inspections · 17 EMA/MHRA GMP certs
Last FDA inspection: 2025-11-14 · NAI
See the evidence →
Curia (RNA/Advanced)
79.5
Albany, NY · Albuquerque, NM
2 FDA inspections · 18 EMA/MHRA GMP certs
Last FDA inspection: 2025-12-02 · NAI
See the evidence →
Kaneka Eurogentec
81.6
Seraing, BE
1 FDA inspection · 4 EMA/MHRA GMP certs
Last FDA inspection: 2024-02-26 · VAI
See the evidence →
Bachem
79.5
Bubendorf, CH
5 FDA inspections · 0 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-20 · VAI
See the evidence →
36
CDMOs tracked
20
Fully scored
14
With FDA records
36
FDA inspections
82
EMA/MHRA GMP certs

Shortlist oligonucleotide CDMOs with Signal

CDMO Signal is an independent sourcing platform ASO, siRNA, and aptamer sponsors use to compare and shortlist oligonucleotide CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then verify chemistry, conjugation, scale, and analytical requirements directly with the shortlisted suppliers.

  1. Compare oligonucleotide CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
  2. Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your ASO, siRNA, or aptamer program's shortlisting criteria.
  3. Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to verify chemistry, conjugation, scale, and analytical requirements directly.

Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.

Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 10 NAI (no action), 26 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: France (37), Italy (16), United States (16), Germany (12), Spain (10).

Last updated 2026-10-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
2
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
83.1 99.3 5 insp · 17 GMP 2025-11-14 · NAI — —
3
KE
Seraing, BE
81.6 99.9 1 insp · 4 GMP 2024-02-26 · VAI — —
4
ND
Milford, MA
80.3 100.0 4 insp · 0 GMP 2026-08-12 · NAI — —
5
BA
Bubendorf, CH
Hiring · 34 open roles
79.5 94.3 5 insp · 0 GMP 2026-05-20 · VAI — —
6
CRA
Albany, NY · Albuquerque, NM
Hiring · 48 open roles
79.5 100.0 2 insp · 18 GMP 2025-12-02 · NAI — —
7
PP
Torrance, CA · Strasbourg, FR · Malmo, SE
Hiring · 33 open roles
77.4 98.4 3 insp · 0 GMP 2025-05-15 · VAI — —
8
AL
Boulder, CO · Frederick, CO
Fully evidenced
Reagent supplier
74.2 100.0 2 insp · 0 GMP 2026-05-06 · NAI — 1 program
9
AX
Kulmbach, Germany
Fully evidenced
71.8 96.8 4 insp · 0 GMP 2025-01-16 · VAI — 3 programs
10
TL
San Diego, CA
Reagent supplier
63.0 — — None on file — —
11
LG
Petaluma, CA · Middleton, WI
63.0 — — None on file — —
12
SM
Tokyo, JP
Also makes its own products
63.0 — — None on file — —
13
AU
63.0 — — None on file — —
14
RR
Guangzhou, China
59.0 — — None on file — —
15
SP
Seoul, South Korea
59.0 — — None on file — —
16
HB
Singapore (primary operations: Union City, CA / Shanghai, China)
56.5 — — None on file — —
17
BS
Lewisville, TX
Reagent supplier
56.5 — — None on file — —
18
CG2
Wilmington, MA
Reagent supplier
56.5 — — None on file — —
19
MM
Irving, TX
Reagent supplier
56.5 — — None on file — —
20
GR
Sterling, VA
Reagent supplier
56.5 — — None on file — —
—
France
Hiring · 41 open roles
Also makes its own products
Profiled — 4 insp · 39 GMP 2024-03-08 · NAI — —
—
Frankfurt am Main, Germany
Profiled — 1 insp · 0 GMP 2022-11-15 · VAI — —
—
Shanghai, China
Also makes its own products
Profiled — 2 insp · 3 GMP 2024-10-18 · VAI — —
—
Lianyungang, Jiangsu, China
Profiled — — None on file — —
—
Shanghai, China
Also makes its own products
Profiled — 1 insp · 0 GMP 2026-08-21 · NAI — —
—
Osaka, Japan
Also makes its own products
Profiled — 1 insp · 0 GMP 2023-05-12 · VAI — —
—
Gwacheon, South Korea
Also makes its own products
Profiled — — None on file — —
—
Meishan, Sichuan, China
Also makes its own products
Profiled — 1 insp · 0 GMP 2025-10-24 · VAI — —
—
Hyderabad, Telangana, India
Profiled — — None on file — —
—
Huizhou, Guangdong, China
Profiled — — None on file — —
—
Toyama, Japan
Profiled — — None on file — —
—
Rudong, Nantong, Jiangsu, China
Profiled — — None on file — —
—
Choshi, Chiba, Japan
Also makes its own products
Profiled — — None on file — —
—
Kyoto, Japan (GMP purification plant: Komatsu, Ishikawa)
Also makes its own products
Profiled — — None on file — —
—
Sanmen, Zhejiang, China
Also makes its own products
Profiled — — None on file — —
—
Knoxville, Tennessee, USA
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a Oligonucleotide / ASO CDMO

Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Oligonucleotide / ASO CDMOs — Frequently Asked Questions

How many Oligonucleotide / ASO CDMOs have FDA inspection records?
CDMO Signal tracks 14 Oligonucleotide / ASO CDMOs with FDA inspection records and 82 EMA/MHRA GMP certificates across the group.
What should I look for in an oligonucleotide CDMO?
Match synthesis scale to your demand, confirm experience with your backbone chemistry and any conjugation (e.g. GalNAc), prioritize strong purity analytics, and a clean FDA and EMA/MHRA record.
What therapeutics do oligonucleotide CDMOs make?
Antisense oligonucleotides (ASOs), siRNAs, aptamers, and related nucleic-acid drugs — increasingly with conjugation chemistries like GalNAc for targeted delivery.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Oligo/ASO shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Plasmid DNA CDMOs mRNA / LNP CDMOs Biologics / mAb CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector